首页 > 最新文献

Journal of Pharmaceutical Innovation最新文献

英文 中文
Application of Liquisolid Pellets Technology for Improving Dissolution of Posaconazole: A DoE Based Process Optimization 应用 Liquisolid 颗粒技术提高泊沙康唑的溶解度:基于 DoE 的工艺优化
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-24 DOI: 10.1007/s12247-024-09830-0
Sunny Shah, Parth Devani, Kiran Dudhat, Ashvin Dudhrejiya, Chandankumar Pashavan, Dhavalkumar Mori

Purpose

Posaconazole (PSZ) is BCS class-II drug that displays variable bioavailability upon oral administration due to extremely low and pH-dependent solubility.

Method

The present investigation was aimed to formulate and evaluate liquisolid pellets of PSZ for improving its dissolution. Liquisolid pellets were prepared using Transcutol® HP, Neusilin® US2, and Aerosil® 200 as non-volatile liquid, carrier, and coating materials respectively. A 32 full factorial design having excipient ratio (R) and spheronization speed as independent variables and the cumulative amount of drug dissolved at 135 min and 165 min as dependent variables were used for the process optimization.

Result

The results of regression analysis indicated a significant effect of selected independent variables on the dependent variables (p-value < 0.05). Differential scanning calorimetry (DSC) studies revealed that the PSZ remained in an amorphous or molecular dispersed state within the liquisolid pellets. Powder X-ray diffraction (PXRD) analysis indicated a significant reduction in crystallinity of the entrapped drug compared to pure drugs. The Fourier-transform infrared (FTIR) analysis demonstrated the stability of the drug within the optimized pellets. SEM images confirmed uniform and well-shaped spherical liquisolid pellets.

Conclusion

During In-vitro dissolution studies, the cumulative amount of the drug dissolved from the prepared pellets was less than 5% during the acid stage (750 ml 0.01 N HCL) whereas the improvement was significant during the buffer stage (750 ml 0.01 N HCL + 250 ml 0.2 M pH 6.8 Phosphate buffer + 1.46% polysorbate 80).

目的泊沙康唑(Posaconazole,PSZ)是一种 BCS II 类药物,由于其溶解度极低,且与 pH 值有关,因此口服后的生物利用度不稳定。采用 Transcutol® HP、Neusilin® US2 和 Aerosil® 200 分别作为非挥发性液体、载体和包衣材料,制备了液固颗粒。结果回归分析结果表明,所选自变量对因变量有显著影响(p 值为 0.05)。差示扫描量热法(DSC)研究表明,PSZ 在液固颗粒中保持无定形或分子分散状态。粉末 X 射线衍射(PXRD)分析表明,与纯药物相比,夹带药物的结晶度显著降低。傅立叶变换红外(FTIR)分析表明,药物在优化后的颗粒中具有稳定性。结论在体外溶解研究中,在酸性阶段(750 毫升 0.01 N HCL),从制备的颗粒中溶解的药物累积量低于 5%,而在缓冲阶段(750 毫升 0.01 N HCL + 250 毫升 0.2 M pH 6.8 磷酸盐缓冲液 + 1.46% 聚山梨醇酯 80),药物溶解量有了显著提高。
{"title":"Application of Liquisolid Pellets Technology for Improving Dissolution of Posaconazole: A DoE Based Process Optimization","authors":"Sunny Shah,&nbsp;Parth Devani,&nbsp;Kiran Dudhat,&nbsp;Ashvin Dudhrejiya,&nbsp;Chandankumar Pashavan,&nbsp;Dhavalkumar Mori","doi":"10.1007/s12247-024-09830-0","DOIUrl":"10.1007/s12247-024-09830-0","url":null,"abstract":"<div><h3>Purpose</h3><p>Posaconazole (PSZ) is BCS class-II drug that displays variable bioavailability upon oral administration due to extremely low and pH-dependent solubility.</p><h3>Method</h3><p>The present investigation was aimed to formulate and evaluate liquisolid pellets of PSZ for improving its dissolution. Liquisolid pellets were prepared using Transcutol® HP, Neusilin® US2, and Aerosil® 200 as non-volatile liquid, carrier, and coating materials respectively. A 3<sup>2</sup> full factorial design having excipient ratio (R) and spheronization speed as independent variables and the cumulative amount of drug dissolved at 135 min and 165 min as dependent variables were used for the process optimization.</p><h3>Result</h3><p>The results of regression analysis indicated a significant effect of selected independent variables on the dependent variables (<i>p</i>-value &lt; 0.05). Differential scanning calorimetry (DSC) studies revealed that the PSZ remained in an amorphous or molecular dispersed state within the liquisolid pellets. Powder X-ray diffraction (PXRD) analysis indicated a significant reduction in crystallinity of the entrapped drug compared to pure drugs. The Fourier-transform infrared (FTIR) analysis demonstrated the stability of the drug within the optimized pellets. SEM images confirmed uniform and well-shaped spherical liquisolid pellets.</p><h3>Conclusion</h3><p>During <i>In-vitro</i> dissolution studies, the cumulative amount of the drug dissolved from the prepared pellets was less than 5% during the acid stage (750 ml 0.01 N HCL) whereas the improvement was significant during the buffer stage (750 ml 0.01 N HCL + 250 ml 0.2 M pH 6.8 Phosphate buffer + 1.46% polysorbate 80).</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"19 3","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140660944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancing the Entrapment Efficiency of Alginate Floating Beads Using Double Emulsion Technique 利用双乳液技术提高藻酸盐浮珠的包埋效率
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-23 DOI: 10.1007/s12247-024-09831-z
Ali Alazzo, Alaa Altaie, Radhwan Al-Zidan, Hayder Alhamdany, Noralhuda Akram Yahya, Noora Th. Aldabbagh

Purpose

Alginate beads intended to float in the stomach have several advantages over the traditional oral dosage forms. However, the formulation of these beads to deliver hydrophilic drugs such as captopril is a big challenge in terms of entrapment efficiency (EE) and extending the drug release. Here, we investigated the feasibility of using the double emulsion (DE) technique during the preparation of alginate floating beads to enhance the EE. This technique allows the incorporation of captopril into the oil droplets, the floating agent within the beads, which provides a hydrophobic barrier preventing drug loss.

Methods

Different DE beads were prepared using ionotropic gelation methods and compared with ordinary oil-entrapped beads based on the floating properties, EE, and drug release.

Results

The results revealed that all the prepared beads have comparable floating properties, however, the EE was significantly increased from 11% for ordinary beads to 25% for DE beads. Moreover, the release of captopril from DE beads was markedly prolonged in comparison to that from ordinary beads. The SEM images clearly showed that the use of surfactant, tween 80, has a significant effect on the prepared beads through stabilizing the primary emulsion, maintain the drug dispersed within the oil droplets, and producing smooth beads with well-crosslinked surface and small well-dispersed oil droplets.

Conclusion

The findings of this study highlighted the potential of DE alginate beads as a promising drug delivery system, addressing the challenges associated with hydrophilic drug encapsulation.

目的 与传统的口服剂型相比,可漂浮在胃中的海藻酸珠具有多种优势。然而,如何配制这种珠子来递送卡托普利等亲水性药物,在夹持效率(EE)和延长药物释放时间方面是一个巨大的挑战。在此,我们研究了在制备藻酸盐浮珠时使用双乳液(DE)技术来提高 EE 的可行性。方法采用离子凝胶法制备不同的双乳化珠,并根据其漂浮性能、EE 和药物释放情况与普通的油包珠进行比较。结果结果表明,所有制备的珠子都具有相似的漂浮性能,但 DE 珠的 EE 从普通珠子的 11% 显著增加到 25%。此外,与普通珠子相比,DE 珠子的卡托普利释放时间明显延长。扫描电子显微镜图像清楚地表明,表面活性剂吐温 80 的使用对制备的珠子有显著效果,它能稳定初乳液,保持药物在油滴中的分散,并产生表面交联良好、油滴分散良好的光滑珠子。
{"title":"Enhancing the Entrapment Efficiency of Alginate Floating Beads Using Double Emulsion Technique","authors":"Ali Alazzo,&nbsp;Alaa Altaie,&nbsp;Radhwan Al-Zidan,&nbsp;Hayder Alhamdany,&nbsp;Noralhuda Akram Yahya,&nbsp;Noora Th. Aldabbagh","doi":"10.1007/s12247-024-09831-z","DOIUrl":"10.1007/s12247-024-09831-z","url":null,"abstract":"<div><h3>Purpose</h3><p>Alginate beads intended to float in the stomach have several advantages over the traditional oral dosage forms. However, the formulation of these beads to deliver hydrophilic drugs such as captopril is a big challenge in terms of entrapment efficiency (EE) and extending the drug release. Here, we investigated the feasibility of using the double emulsion (DE) technique during the preparation of alginate floating beads to enhance the EE. This technique allows the incorporation of captopril into the oil droplets, the floating agent within the beads, which provides a hydrophobic barrier preventing drug loss.</p><h3>Methods</h3><p>Different DE beads were prepared using ionotropic gelation methods and compared with ordinary oil-entrapped beads based on the floating properties, EE, and drug release.</p><h3>Results</h3><p>The results revealed that all the prepared beads have comparable floating properties, however, the EE was significantly increased from 11% for ordinary beads to 25% for DE beads. Moreover, the release of captopril from DE beads was markedly prolonged in comparison to that from ordinary beads. The SEM images clearly showed that the use of surfactant, tween 80, has a significant effect on the prepared beads through stabilizing the primary emulsion, maintain the drug dispersed within the oil droplets, and producing smooth beads with well-crosslinked surface and small well-dispersed oil droplets.</p><h3>Conclusion</h3><p>The findings of this study highlighted the potential of DE alginate beads as a promising drug delivery system, addressing the challenges associated with hydrophilic drug encapsulation.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"19 3","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140671954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Simple Approach to Preparation of Surfactant Nano-Micelles Loaded Drugs 制备含有药物的表面活性剂纳米微粒的简单方法
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-22 DOI: 10.1007/s12247-024-09827-9
Mohammed S. Al-lami, Malathe A Alshawi, Farouq M. Saker

The ability to formulate optimum drug-loaded carriers is a challenge that impedes virtuous drug delivery and stability. Nano micelles (NMs) are highly prospective carriers due to their minute dimensions and exceptional biocompatibility. This study investigated a more efficient and straightforward fabrication method for surfactant nano micelles than the conventional solvent vaporization process. The objective was to develop and validate the Direct Method, an expedited approach for producing surfactant NMs. Tween 20, was employed to simulate the solubility of various drugs in Surfactant, including azithromycin monohydrate, fusidic acid, and metronidazole. Four distinct concentrations of the medication were employed. The polydispersity index and micellar diameter were employed to compare and contrast the two methodologies. No significant differences (p < 0.05) were observed between the outcomes obtained from both methods, irrespective of the concentrations of the drugs. The Direct Method exhibited comparable levels of efficiency to the conventional approach. The study effectively established the Direct Method as a rapid and efficient substitute for surfactant NMs synthesis.

能否配制出最佳的药物载体是一项挑战,它阻碍了药物的良性输送和稳定性。纳米胶束(NMs)因其微小的尺寸和优异的生物相容性而成为极具前景的载体。本研究探讨了一种比传统溶剂汽化工艺更高效、更直接的表面活性剂纳米胶束制造方法。目的是开发和验证直接法,这是一种生产表面活性剂纳米胶束的快速方法。采用吐温 20 来模拟各种药物在表面活性剂中的溶解度,包括一水阿奇霉素、夫西地酸和甲硝唑。采用了四种不同浓度的药物。采用多分散指数和胶束直径来比较和对比两种方法。无论药物浓度如何,两种方法得出的结果均无明显差异(p < 0.05)。直接法的效率与传统方法相当。这项研究有效地确立了直接法作为表面活性剂 NMs 合成的快速、高效替代方法的地位。
{"title":"A Simple Approach to Preparation of Surfactant Nano-Micelles Loaded Drugs","authors":"Mohammed S. Al-lami,&nbsp;Malathe A Alshawi,&nbsp;Farouq M. Saker","doi":"10.1007/s12247-024-09827-9","DOIUrl":"10.1007/s12247-024-09827-9","url":null,"abstract":"<div><p>The ability to formulate optimum drug-loaded carriers is a challenge that impedes virtuous drug delivery and stability. Nano micelles (NMs) are highly prospective carriers due to their minute dimensions and exceptional biocompatibility. This study investigated a more efficient and straightforward fabrication method for surfactant nano micelles than the conventional solvent vaporization process. The objective was to develop and validate the Direct Method, an expedited approach for producing surfactant NMs. Tween 20, was employed to simulate the solubility of various drugs in Surfactant, including azithromycin monohydrate, fusidic acid, and metronidazole. Four distinct concentrations of the medication were employed. The polydispersity index and micellar diameter were employed to compare and contrast the two methodologies. No significant differences (<i>p</i> &lt; 0.05) were observed between the outcomes obtained from both methods, irrespective of the concentrations of the drugs. The Direct Method exhibited comparable levels of efficiency to the conventional approach. The study effectively established the Direct Method as a rapid and efficient substitute for surfactant NMs synthesis.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"19 3","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140634298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
“Implementation of Quality by Design of Sublingual Antihypertensive Drugs" "通过设计提高舌下含服降压药的质量 "的实施情况
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-20 DOI: 10.1007/s12247-024-09832-y
Deepak Joshi, Naveen K. Choudhary

Background

Hypertension poses a global health challenge, contributing significantly to mortality and cardiovascular diseases in both developed and low- to middle-income nations. Conventional oral tablets often fail to provide the rapid onset required for acute conditions, prompting exploration of alternative non-parenteral routes.

Main Body

This review focuses on sublingual administration as a viable option, given its potential for rapid drug absorption due to the sublingual cavity's higher permeability. Sublingual tablets offer advantages such as improved bioavailability, minimal adverse effects, and ease of use. However, formulating effective sublingual tablets presents challenges distinct from conventional tablets QbD, or quality by design, is a methodical approach to formulation development., offering benefits like high-quality pharmaceuticals, regulatory flexibility, and post-approval modification management. The QbD process involves defining quality target product profiles, understanding manufacturing processes, identifying critical material attributes, and optimizing key process parameters. This systematic approach ensures a design space that allows for constant improvement throughout the pharmaceutical product lifecycle.

Conclusion

This review aims to consolidate studies on sublingual administration of antihypertensive drugs, incorporating a systematic risk assessment approach within the QbD framework. By applying QbD principles to optimize sublingual tablet formulations, this approach promises efficient drug product development, reducing the need for extensive testing while ensuring affordability and effectiveness. Despite numerous literature reviews on sublingual tablets, this review uniquely addresses the systematic implementation of QbD for sublingual tablet development, filling a gap in the current pharmaceutical research landscape. The exploration of risk identification, analysis, and evaluation of critical quality attributes enhances our understanding of antihypertensive sublingual tablets' development, providing a valuable resource for pharmaceutical scientists and researchers.

Graphical Abstract

背景高血压是一项全球健康挑战,在发达国家和中低收入国家都是导致死亡率和心血管疾病的重要因素。由于舌下腔具有较高的渗透性,因此具有快速吸收药物的潜力,传统的口服片剂往往无法提供急性病症所需的快速起效,这促使人们探索其他非肠道途径。舌下片剂具有生物利用度高、不良反应小和使用方便等优点。然而,配制有效的舌下片剂面临着不同于传统片剂的挑战 QbD 或质量源于设计,是一种有条不紊的制剂开发方法,具有高质量药品、监管灵活性和批准后修改管理等优点。QbD 流程包括定义目标产品的质量特性、了解生产工艺、确定关键材料属性以及优化关键工艺参数。本综述旨在整合有关舌下含服降压药的研究,将系统风险评估方法纳入 QbD 框架。通过应用 QbD 原则优化舌下片剂配方,这种方法有望实现高效的药物产品开发,减少对大量测试的需求,同时确保药物的经济性和有效性。尽管有关舌下片剂的文献综述不胜枚举,但本综述却独树一帜地探讨了在舌下片剂开发中系统实施 QbD 的问题,填补了当前药物研究领域的空白。对关键质量属性的风险识别、分析和评估的探讨,增强了我们对降压药舌下片开发的理解,为制药科学家和研究人员提供了宝贵的资源。
{"title":"“Implementation of Quality by Design of Sublingual Antihypertensive Drugs\"","authors":"Deepak Joshi,&nbsp;Naveen K. Choudhary","doi":"10.1007/s12247-024-09832-y","DOIUrl":"10.1007/s12247-024-09832-y","url":null,"abstract":"<div><h3>Background</h3><p>Hypertension poses a global health challenge, contributing significantly to mortality and cardiovascular diseases in both developed and low- to middle-income nations. Conventional oral tablets often fail to provide the rapid onset required for acute conditions, prompting exploration of alternative non-parenteral routes.</p><h3>Main Body</h3><p>This review focuses on sublingual administration as a viable option, given its potential for rapid drug absorption due to the sublingual cavity's higher permeability. Sublingual tablets offer advantages such as improved bioavailability, minimal adverse effects, and ease of use. However, formulating effective sublingual tablets presents challenges distinct from conventional tablets QbD, or quality by design, is a methodical approach to formulation development., offering benefits like high-quality pharmaceuticals, regulatory flexibility, and post-approval modification management. The QbD process involves defining quality target product profiles, understanding manufacturing processes, identifying critical material attributes, and optimizing key process parameters. This systematic approach ensures a design space that allows for constant improvement throughout the pharmaceutical product lifecycle.</p><h3>Conclusion</h3><p>This review aims to consolidate studies on sublingual administration of antihypertensive drugs, incorporating a systematic risk assessment approach within the QbD framework. By applying QbD principles to optimize sublingual tablet formulations, this approach promises efficient drug product development, reducing the need for extensive testing while ensuring affordability and effectiveness. Despite numerous literature reviews on sublingual tablets, this review uniquely addresses the systematic implementation of QbD for sublingual tablet development, filling a gap in the current pharmaceutical research landscape. The exploration of risk identification, analysis, and evaluation of critical quality attributes enhances our understanding of antihypertensive sublingual tablets' development, providing a valuable resource for pharmaceutical scientists and researchers.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"19 3","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140626650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liquid Crystal Nanoparticles-based Fluocinolone Acetonide Topical Gel for Atopic Dermatitis: In vitro and in vivo Study 用于特应性皮炎的液晶纳米颗粒氟西诺龙-阿塞通内酯外用凝胶:体外和体内研究
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-17 DOI: 10.1007/s12247-024-09829-7
Chaitanya Shirke, Sarika Wairkar

Purpose

Fluocinolone acetonide is a potent anti-inflammatory corticosteroid commonly used to treat atopic dermatitis. Its commercially available topical formulations (cream/ointment) must be administered frequently. The study aimed to develop a fluocinolone acetonide-liquid crystal nanoparticles (FA-LCN) based gel for treating atopic dermatitis.

Methods

FA-LCN were produced using a top-down method and statistically optimized by a 23 full-factorial design with concentrations of glyceryl monooleate, Poloxamer 407 and sonication time as independent variables, while entrapment efficacy (EE), particle size (PS) and in vitro drug release (DR) as dependent variables.

Results

The optimized batch with an average particle size of 265.3 nm, zeta potential of -47.3 mV and encapsulation efficiency of 98.6% was incorporated into Carbopol 940-based gel. The globular nanoparticles were confirmed by TEM analysis, and their formation was supported by FTIR data. In vitro studies of FA-LCN gel showed 96 ± 1.65% release at the end of 30 h. In vivo studies revealed no skin irritation after the application of FA-LCN gel. FA-LCN (0.5%w/w) gel showed faster healing, substantially reduced earflap thickness, and lower WBC counts compared to the FA-LCN 0.1% gel and the marketed formulation in albino Wistar rats challenged with DNCB. Additionally, the FA-LCN 0.5% gel (3.08 ± 0.16 µg/cm2) exhibited greater drug deposition in the skin compared to the FA-LCN 0.1% (2.12 ± 0.11 µg/cm2) gel and the marketed formulation (1.01 ± 0.19 µg/cm2).

Conclusions

Therefore, FA-LCN-based gel could be a viable option for chronic dermatological treatment for atopic dermatitis with a reduced application frequency.

目的氟西诺龙丙酮是一种强效消炎皮质类固醇,常用于治疗特应性皮炎。其市售外用制剂(霜剂/膏剂)必须频繁使用。该研究旨在开发一种基于氟西诺龙-丙酮液晶纳米颗粒(FA-LCN)的凝胶,用于治疗特应性皮炎。方法采用自上而下的方法生产 FA-LCN,并通过 23 全因子设计进行统计优化,以甘油单油酸酯、Poloxamer 407 的浓度和超声时间为自变量,以夹持效力(EE)、粒度(PS)和体外药物释放(DR)为因变量。结果将平均粒径为265.3 nm、zeta电位为-47.3 mV、包封效率为98.6%的优化批次纳入Carbopol 940凝胶中。球状纳米颗粒经 TEM 分析证实,其形成得到了傅立叶变换红外光谱数据的支持。体外研究显示,FA-LCN凝胶在30小时后的释放量为96 ± 1.65%。与 FA-LCN 0.1%凝胶和市场上销售的配方相比,FA-LCN(0.5%w/w)凝胶在白化 Wistar 大鼠的 DNCB 治疗中显示出更快的愈合速度、大幅减少的耳瓣厚度和更低的白细胞计数。此外,与 FA-LCN 0.1%凝胶(2.12 ± 0.11 µg/cm2)和市售配方(1.01 ± 0.19 µg/cm2)相比,FA-LCN 0.5%凝胶(3.08 ± 0.16 µg/cm2)在皮肤中的药物沉积更多。
{"title":"Liquid Crystal Nanoparticles-based Fluocinolone Acetonide Topical Gel for Atopic Dermatitis: In vitro and in vivo Study","authors":"Chaitanya Shirke,&nbsp;Sarika Wairkar","doi":"10.1007/s12247-024-09829-7","DOIUrl":"10.1007/s12247-024-09829-7","url":null,"abstract":"<div><h3>Purpose</h3><p>Fluocinolone acetonide is a potent anti-inflammatory corticosteroid commonly used to treat atopic dermatitis. Its commercially available topical formulations (cream/ointment) must be administered frequently. The study aimed to develop a fluocinolone acetonide-liquid crystal nanoparticles (FA-LCN) based gel for treating atopic dermatitis.</p><h3>Methods</h3><p>FA-LCN were produced using a top-down method and statistically optimized by a 2<sup>3</sup> full-factorial design with concentrations of glyceryl monooleate, Poloxamer 407 and sonication time as independent variables, while entrapment efficacy (EE), particle size (PS) and in vitro drug release (DR) as dependent variables.</p><h3>Results</h3><p>The optimized batch with an average particle size of 265.3 nm, zeta potential of -47.3 mV and encapsulation efficiency of 98.6% was incorporated into Carbopol 940-based gel. The globular nanoparticles were confirmed by TEM analysis, and their formation was supported by FTIR data. In vitro studies of FA-LCN gel showed 96 ± 1.65% release at the end of 30 h. In vivo studies revealed no skin irritation after the application of FA-LCN gel. FA-LCN (0.5%w/w) gel showed faster healing, substantially reduced earflap thickness, and lower WBC counts compared to the FA-LCN 0.1% gel and the marketed formulation in albino Wistar rats challenged with DNCB. Additionally, the FA-LCN 0.5% gel (3.08 ± 0.16 µg/cm<sup>2</sup>) exhibited greater drug deposition in the skin compared to the FA-LCN 0.1% (2.12 ± 0.11 µg/cm<sup>2</sup>) gel and the marketed formulation (1.01 ± 0.19 µg/cm<sup>2</sup>).</p><h3>Conclusions</h3><p>Therefore, FA-LCN-based gel could be a viable option for chronic dermatological treatment for atopic dermatitis with a reduced application frequency.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"19 3","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140612152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deep Eutectic System-Based Liquisolid Nanoparticles as Drug Delivery System of Curcumin for In-Vitro Colon Cancer Cells 基于深共晶体系的栗胶纳米颗粒作为姜黄素的体外结肠癌细胞给药系统
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-09 DOI: 10.1007/s12247-024-09826-w
Abdeh Nakaweh, Faisal Al-Akayleh, Mayyas Al-Remawi, Qasem Abdallah, Ahmed S.A. Ali Agha

Purpose

This study aims to improve curcumin’s solubility and anti-cancer effectiveness by utilizing deep eutectic solvents (DES)-based liquisolid nanoparticles. This study aims to develop mesoporous silica nanoparticles (MSNs) containing curcumin and evaluate their therapeutic efficacy against the HCT 116 human colon cancer cell line.

Methods

The study focused on developing different DES formulations using Menthol and Capric Acid, evaluating the effectiveness of surfactants such as Labrasol and Tween 80 in enhancing curcumin dissolution, and synthesizing curcumin-loaded MSNs. The stability of nanoparticles in deep eutectic solvents (DES) and their pharmacological impact on colon cancer cells were thoroughly assessed.

Results

The solubility of curcumin was significantly enhanced through the use of deep eutectic solvent (DES) formulations, specifically when Tween 80 was employed as a surfactant. The in vitro tests showed that curcumin-loaded MSNs with Tween 80 demonstrated strong anti-cancer activity, as indicated by an IC50 value of around 100 µM.

Conclusion

The study effectively shows that DES-based MSNs can greatly improve curcumin’s solubility and anti-cancer effectiveness. Tween 80, as a surfactant, enhances its therapeutic potential, indicating promising prospects for future clinical applications in cancer treatment.

目的 本研究旨在利用基于深共晶溶剂(DES)的液态固体纳米粒子提高姜黄素的溶解度和抗癌效果。本研究旨在开发含有姜黄素的介孔二氧化硅纳米颗粒(MSNs),并评估其对 HCT 116 人结肠癌细胞系的疗效。研究重点是使用薄荷醇和癸酸开发不同的 DES 配方,评估 Labrasol 和吐温 80 等表面活性剂在提高姜黄素溶解度方面的效果,并合成含有姜黄素的 MSNs。结果通过使用深共晶溶剂(DES)配方,特别是使用吐温 80 作为表面活性剂,姜黄素的溶解度显著提高。体外测试表明,使用 Tween 80 的姜黄素负载 MSN 具有很强的抗癌活性,其 IC50 值约为 100 µM。作为一种表面活性剂,吐温 80 增强了姜黄素的治疗潜力,为未来在癌症治疗领域的临床应用提供了广阔的前景。
{"title":"Deep Eutectic System-Based Liquisolid Nanoparticles as Drug Delivery System of Curcumin for In-Vitro Colon Cancer Cells","authors":"Abdeh Nakaweh,&nbsp;Faisal Al-Akayleh,&nbsp;Mayyas Al-Remawi,&nbsp;Qasem Abdallah,&nbsp;Ahmed S.A. Ali Agha","doi":"10.1007/s12247-024-09826-w","DOIUrl":"10.1007/s12247-024-09826-w","url":null,"abstract":"<div><h3>Purpose</h3><p>This study aims to improve curcumin’s solubility and anti-cancer effectiveness by utilizing deep eutectic solvents (DES)-based liquisolid nanoparticles. This study aims to develop mesoporous silica nanoparticles (MSNs) containing curcumin and evaluate their therapeutic efficacy against the HCT 116 human colon cancer cell line.</p><h3>Methods</h3><p>The study focused on developing different DES formulations using Menthol and Capric Acid, evaluating the effectiveness of surfactants such as Labrasol and Tween 80 in enhancing curcumin dissolution, and synthesizing curcumin-loaded MSNs. The stability of nanoparticles in deep eutectic solvents (DES) and their pharmacological impact on colon cancer cells were thoroughly assessed.</p><h3>Results</h3><p>The solubility of curcumin was significantly enhanced through the use of deep eutectic solvent (DES) formulations, specifically when Tween 80 was employed as a surfactant. The in vitro tests showed that curcumin-loaded MSNs with Tween 80 demonstrated strong anti-cancer activity, as indicated by an IC50 value of around 100 µM.</p><h3>Conclusion</h3><p>The study effectively shows that DES-based MSNs can greatly improve curcumin’s solubility and anti-cancer effectiveness. Tween 80, as a surfactant, enhances its therapeutic potential, indicating promising prospects for future clinical applications in cancer treatment.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"19 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140579649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In Vitro Profiling of Gliclazide-Loaded Aerosil 380 Solid Dispersion–Based Tablets with Co-Processed Excipients 加载了格列齐特的 Aerosil 380 固体分散剂片剂与共处理辅料的体外剖面分析
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-03 DOI: 10.1007/s12247-024-09817-x
Israt Zerin Alam, Jakia Sultana, Mohsin Kazi, Mohammad N. Uddin, Md Bytul Mokaddesur Rahman
<div><h3>Purpose</h3><p>Gliclazide (GLC)-loaded Aerosil 380 solid dispersion (GA-SD)-based tablets with co-processed excipient composites were formulated to critically evaluate the physicochemical performance of the resulting tablets with enhanced drug release.</p><h3>Methods</h3><p>GA-SD was prepared using the solvent evaporation method with a 1:1 weight ratio based on a previously published report, and its drug release patterns were evaluated. Processed excipient composites, such as lactose-starch-povidone (LSP) and lactose-starch-povidone-sodium starch glycolate (LSPS), were prepared via a coprocessing strategy and evaluated for their ability to perform specific functions. At predetermined combination levels, aqueous dispersions of primary excipients were physically agglomerated at a controlled temperature below the gelatinization temperature (55 °C) before drying at 60 °C for 48 h. GA-SD and co-processed excipients (LSP and LSPS) were utilized to produce tablet batches GAC1 to GAC8 (Gliclazide-Aerosil 380–co-processed excipients, GAC) by direct compression. Through rigorous testing of tablet batches, the physicochemical properties of the resulting formulations were analyzed and compared to those of leading marketed formulations (MFs). FTIR studies were also conducted to detect drug-excipient interactions in the tablet formulations. The release mechanism of the GLC was determined by studying the dissolution process with various kinetic models. The GAC tablets were subjected to 40 °C/75% RH for 3 months to assess stability.</p><h3>Results</h3><p>All tablet formulations of GA-SD containing co-processed excipients met the weight, friability, disintegration time, mechanical strength, and homogeneity requirements. There was significantly more GLC released from the GAC formulations (<i>p</i> < 0.05) at each time point when the formulations were exposed to water than when the formulations were exposed to MFs. In vitro, testing revealed that the GAC5 to GAC8 formulations were the most efficient due to the presence of the superdisintegrant in the LSPS composite, which may be a contributing factor to the improvement in the dissolution rate by GA-SD. FTIR analysis revealed no notable chemical interactions between GLC and the excipients in the solid state. The Korsmeyer-Peppas model was the best-fit kinetic model, indicating that diffusion is the predominant mechanism of GLC dissolution. According to the commercial standards, the GAC tablets maintained an acceptable hardness, disintegration time, and drug content during the stability studies. Additionally, no significant changes in release profiles were observed in the selected batches (<i>p</i> < 0.05).</p><h3>Conclusion</h3><p>Compared with currently marketed formulations (MFs), GA-SD tablet formulations with co-processed excipients significantly improved the physicochemical properties, including the drug release rate. These findings could lead to the development of more effective and efficient ta
目的 配制了基于Aerosil 380固体分散体(GA-SD)的加载格列齐特(GLC)的片剂和共加工辅料复合片剂,以严格评估所得片剂的理化性能和药物释放增强效果。方法 根据之前发表的报告,采用溶剂蒸发法以1:1的重量比制备了GA-SD,并评估了其药物释放模式。通过共处理策略制备了乳糖-淀粉-丙维酮(LSP)和乳糖-淀粉-丙维酮-淀粉乙醇酸钠(LSPS)等加工辅料复合材料,并对其执行特定功能的能力进行了评估。在预先确定的组合水平下,在低于糊化温度(55 °C)的受控温度下对主辅料的水分散体进行物理凝集,然后在 60 °C 下干燥 48 小时。GA-SD 和共处理辅料(LSP 和 LSPS)被用于通过直接压缩生产片剂批次 GAC1 至 GAC8(格列齐特-阿罗西尔 380 共处理辅料,GAC)。通过对各批次片剂的严格测试,分析了所得制剂的理化性质,并与市场上的主要制剂(MFs)进行了比较。此外,还进行了傅立叶变换红外光谱研究,以检测片剂中药物与辅料之间的相互作用。通过使用各种动力学模型研究溶解过程,确定了 GLC 的释放机制。结果所有含有共加工辅料的 GA-SD 片剂都符合重量、易碎性、崩解时间、机械强度和均匀性的要求。在每个时间点,GAC 制剂中释放的 GLC(p < 0.05)在暴露于水的情况下明显多于暴露于 MFs 的情况。体外测试表明,GAC5 至 GAC8 制剂的效率最高,这是因为 LSPS 复合材料中含有超崩解剂,这可能是 GA-SD 提高溶出率的一个因素。傅立叶变换红外分析显示,GLC 与固态辅料之间没有明显的化学作用。Korsmeyer-Peppas 模型是最佳拟合动力学模型,表明扩散是 GLC 溶解的主要机制。根据商业标准,GAC 片剂在稳定性研究期间保持了可接受的硬度、崩解时间和药物含量。结论与目前市场上销售的制剂(MFs)相比,GA-SD 片剂与辅料的协同加工显著改善了其理化性质,包括药物释放率。这些发现有助于开发出更有效、更高效的低水溶性药物片剂固体制剂,而且共处理辅料可作为片剂中直接压片材料的更有效替代品。
{"title":"In Vitro Profiling of Gliclazide-Loaded Aerosil 380 Solid Dispersion–Based Tablets with Co-Processed Excipients","authors":"Israt Zerin Alam,&nbsp;Jakia Sultana,&nbsp;Mohsin Kazi,&nbsp;Mohammad N. Uddin,&nbsp;Md Bytul Mokaddesur Rahman","doi":"10.1007/s12247-024-09817-x","DOIUrl":"10.1007/s12247-024-09817-x","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;p&gt;Gliclazide (GLC)-loaded Aerosil 380 solid dispersion (GA-SD)-based tablets with co-processed excipient composites were formulated to critically evaluate the physicochemical performance of the resulting tablets with enhanced drug release.&lt;/p&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;p&gt;GA-SD was prepared using the solvent evaporation method with a 1:1 weight ratio based on a previously published report, and its drug release patterns were evaluated. Processed excipient composites, such as lactose-starch-povidone (LSP) and lactose-starch-povidone-sodium starch glycolate (LSPS), were prepared via a coprocessing strategy and evaluated for their ability to perform specific functions. At predetermined combination levels, aqueous dispersions of primary excipients were physically agglomerated at a controlled temperature below the gelatinization temperature (55 °C) before drying at 60 °C for 48 h. GA-SD and co-processed excipients (LSP and LSPS) were utilized to produce tablet batches GAC1 to GAC8 (Gliclazide-Aerosil 380–co-processed excipients, GAC) by direct compression. Through rigorous testing of tablet batches, the physicochemical properties of the resulting formulations were analyzed and compared to those of leading marketed formulations (MFs). FTIR studies were also conducted to detect drug-excipient interactions in the tablet formulations. The release mechanism of the GLC was determined by studying the dissolution process with various kinetic models. The GAC tablets were subjected to 40 °C/75% RH for 3 months to assess stability.&lt;/p&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;All tablet formulations of GA-SD containing co-processed excipients met the weight, friability, disintegration time, mechanical strength, and homogeneity requirements. There was significantly more GLC released from the GAC formulations (&lt;i&gt;p&lt;/i&gt; &lt; 0.05) at each time point when the formulations were exposed to water than when the formulations were exposed to MFs. In vitro, testing revealed that the GAC5 to GAC8 formulations were the most efficient due to the presence of the superdisintegrant in the LSPS composite, which may be a contributing factor to the improvement in the dissolution rate by GA-SD. FTIR analysis revealed no notable chemical interactions between GLC and the excipients in the solid state. The Korsmeyer-Peppas model was the best-fit kinetic model, indicating that diffusion is the predominant mechanism of GLC dissolution. According to the commercial standards, the GAC tablets maintained an acceptable hardness, disintegration time, and drug content during the stability studies. Additionally, no significant changes in release profiles were observed in the selected batches (&lt;i&gt;p&lt;/i&gt; &lt; 0.05).&lt;/p&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;p&gt;Compared with currently marketed formulations (MFs), GA-SD tablet formulations with co-processed excipients significantly improved the physicochemical properties, including the drug release rate. These findings could lead to the development of more effective and efficient ta","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"19 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140579655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel Chitosan Beeswax Matrix for Gastro-Retentive Delivery of Curcumin: A Promising Adjuvant Therapy for Helicobacter Infection 新型壳聚糖蜂蜡基质用于姜黄素的胃肠道给药:一种前景看好的螺旋杆菌感染辅助疗法
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-28 DOI: 10.1007/s12247-024-09824-y
Nisrein Jaber, Mayyas Al-Remawi, Rami A. Abdel-Rahem

Purpose

The main purpose of this study is to introduce a new adjuvant treatment for H. pylori that aims to enhance therapy outcomes. The research question is how to create a controlled-release gastro-retentive floating system using a combination of chitosan (CS) and beeswax (BW) and to evaluate the release behavior of curcumin as an active ingredient.

Methods

In this study, a new formula combining CS and BW was developed through a hot melting process to create a controlled-release gastro-retentive floating system. Response surface methodology (RSM) was employed to determine the optimal conditions and concentrations of CS and BW to produce the desired floating system. Parameters such as mixing time, processing melting temperature, and concentration of BW were evaluated.

Results

The study found that the optimal parameters for the CS/BW formulation were determined as follows: a mixing time of 3 min, a processing melting temperature of 92.2 °C, and a BW concentration of 13.3% (w/w). Curcumin was incorporated into the optimal tablet, and its release behavior was evaluated. The results showed a full floating behavior of the tablet and a zero-order release behavior in acidic conditions.

Conclusions

The study successfully introduced a new adjuvant treatment for H. pylori that utilizes a controlled-release gastro-retentive floating system. The combination of CS and BW, along with the incorporation of curcumin, showed promising results in terms of floating behavior and release kinetics. This new treatment approach has the potential to enhance therapy outcomes for H. pylori infections.

目的 本研究的主要目的是引入一种新的幽门螺杆菌辅助治疗方法,以提高治疗效果。研究问题是如何使用壳聚糖(CS)和蜂蜡(BW)的组合来创建一种控释胃肠道留滞浮动系统,并评估姜黄素作为活性成分的释放行为。方法在这项研究中,通过热熔工艺开发了一种结合了壳聚糖和蜂蜡的新配方,以创建一种控释胃肠道留滞浮动系统。采用响应面方法(RSM)确定了 CS 和 BW 的最佳条件和浓度,以生产出所需的漂浮体系。研究发现,CS/BW 配方的最佳参数确定如下:混合时间为 3 分钟,加工熔化温度为 92.2 °C,BW 浓度为 13.3%(重量比)。在最佳片剂中加入姜黄素,并对其释放行为进行了评估。结果表明,片剂具有完全漂浮特性,在酸性条件下具有零阶释放特性。CS 和 BW 的结合以及姜黄素的加入,在漂浮行为和释放动力学方面都显示出了良好的效果。这种新的治疗方法有望提高幽门螺杆菌感染的治疗效果。
{"title":"Novel Chitosan Beeswax Matrix for Gastro-Retentive Delivery of Curcumin: A Promising Adjuvant Therapy for Helicobacter Infection","authors":"Nisrein Jaber,&nbsp;Mayyas Al-Remawi,&nbsp;Rami A. Abdel-Rahem","doi":"10.1007/s12247-024-09824-y","DOIUrl":"10.1007/s12247-024-09824-y","url":null,"abstract":"<div><h3>Purpose</h3><p>The main purpose of this study is to introduce a new adjuvant treatment for <i>H. pylori</i> that aims to enhance therapy outcomes. The research question is how to create a controlled-release gastro-retentive floating system using a combination of chitosan (CS) and beeswax (BW) and to evaluate the release behavior of curcumin as an active ingredient.</p><h3>Methods</h3><p>In this study, a new formula combining CS and BW was developed through a hot melting process to create a controlled-release gastro-retentive floating system. Response surface methodology (RSM) was employed to determine the optimal conditions and concentrations of CS and BW to produce the desired floating system. Parameters such as mixing time, processing melting temperature, and concentration of BW were evaluated.</p><h3>Results</h3><p>The study found that the optimal parameters for the CS/BW formulation were determined as follows: a mixing time of 3 min, a processing melting temperature of 92.2 °C, and a BW concentration of 13.3% (w/w). Curcumin was incorporated into the optimal tablet, and its release behavior was evaluated. The results showed a full floating behavior of the tablet and a zero-order release behavior in acidic conditions.</p><h3>Conclusions</h3><p>The study successfully introduced a new adjuvant treatment for <i>H. pylori</i> that utilizes a controlled-release gastro-retentive floating system. The combination of CS and BW, along with the incorporation of curcumin, showed promising results in terms of floating behavior and release kinetics. This new treatment approach has the potential to enhance therapy outcomes for <i>H. pylori</i> infections.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"19 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140315200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biosynthesis and Characterization of Silver Nanoparticle by Using Artocarpus altilis Fruit Extract for Its Biological Activity 利用阿尔托卡普斯果实提取物生物合成银纳米粒子并鉴定其生物活性
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-27 DOI: 10.1007/s12247-024-09819-9
Thasni PM, Abdul Vajid K, Najila Shirin U, Nivya K, Fathimath Shibila AP, Ilyas UK

Purpose

The study of nanoparticles for antibacterial, antifungal, and anticancer action is an important sector in nanoscience. The use of plant extracts in nanoparticle synthesis is among the most simple, cost-effective, and ecologically acceptable strategies. The goal is to use Artocarpus altilis fruit extract to generate plant-mediated silver nanoparticles for its biological activity.

Methods

Phytochemical profiling of methanolic extract of Artocarpus altilis fruit was carried out. UV visible spectroscopy and scanning electron microscopy (SEM) are used to characterize the sample. The disc diffusion method was used to interpret antimicrobial activity. The MTT assay was used to determine the cytotoxicity.

Results

The presence of flavonoids, terpenoids, phenolic compounds, and others was discovered by phytochemical profiling. UV-visible spectroscopy was used to establish the existence of AgNPs, and a maximum absorbance range was obtained. The optimized nanoparticles were shown to have a spherical shape by the SEM pictures. Using the disc diffusion method, the defined AgNPs demonstrated antibacterial efficacy against Escherichia coli, Pseudomonas aeruginosa, Bacillus subtilis, and Staphylococcus aureus at various doses, as well as antifungal efficacy against Aspergillus fumigates. When compared to doxorubicin, the lung cancer cell lines (A549 cell line) demonstrated potential anticancer activity of silver nanoparticles.

Conclusion

We discovered that silver nanoparticles made from Artocarpus altilis fruit extract have a similar effect to ciprofloxacin. The cytotoxic activity anticipated against the lung cancer cell line (A549 cell line) shows that the percentage of cell viability is identical to that of doxorubicin which indicates the potential for the treatment of lung tumors.

研究纳米粒子的抗菌、抗真菌和抗癌作用是纳米科学的一个重要领域。在纳米粒子合成中使用植物提取物是最简单、最具成本效益和生态可接受性的策略之一。本研究的目标是利用阿尔蒂斯蒿果实提取物生成植物介导的银纳米粒子,以提高其生物活性。方法对阿尔蒂斯蒿果实的甲醇提取物进行了植物化学分析。使用紫外可见光谱和扫描电子显微镜(SEM)对样品进行表征。盘扩散法用于解释抗菌活性。结果通过植物化学分析发现了黄酮类、萜类、酚类等化合物的存在。利用紫外可见光谱确定了 AgNPs 的存在,并获得了最大吸光度范围。扫描电镜照片显示,优化后的纳米粒子呈球形。利用盘扩散法,确定的 AgNPs 在不同剂量下对大肠杆菌、铜绿假单胞菌、枯草杆菌和金黄色葡萄球菌具有抗菌效果,对熏曲霉菌也具有抗真菌效果。与多柔比星相比,银纳米颗粒对肺癌细胞株(A549 细胞株)具有潜在的抗癌活性。对肺癌细胞株(A549 细胞株)的细胞毒活性预期显示,细胞存活率与多柔比星相同,这表明银纳米粒子具有治疗肺部肿瘤的潜力。
{"title":"Biosynthesis and Characterization of Silver Nanoparticle by Using Artocarpus altilis Fruit Extract for Its Biological Activity","authors":"Thasni PM,&nbsp;Abdul Vajid K,&nbsp;Najila Shirin U,&nbsp;Nivya K,&nbsp;Fathimath Shibila AP,&nbsp;Ilyas UK","doi":"10.1007/s12247-024-09819-9","DOIUrl":"10.1007/s12247-024-09819-9","url":null,"abstract":"<div><h3>Purpose</h3><p>The study of nanoparticles for antibacterial, antifungal, and anticancer action is an important sector in nanoscience. The use of plant extracts in nanoparticle synthesis is among the most simple, cost-effective, and ecologically acceptable strategies. The goal is to use <i>Artocarpus altilis</i> fruit extract to generate plant-mediated silver nanoparticles for its biological activity.</p><h3>Methods</h3><p>Phytochemical profiling of methanolic extract of <i>Artocarpus altilis</i> fruit was carried out. UV visible spectroscopy and scanning electron microscopy (SEM) are used to characterize the sample. The disc diffusion method was used to interpret antimicrobial activity. The MTT assay was used to determine the cytotoxicity.</p><h3>Results</h3><p>The presence of flavonoids, terpenoids, phenolic compounds, and others was discovered by phytochemical profiling. UV-visible spectroscopy was used to establish the existence of AgNPs, and a maximum absorbance range was obtained. The optimized nanoparticles were shown to have a spherical shape by the SEM pictures. Using the disc diffusion method, the defined AgNPs demonstrated antibacterial efficacy against <i>Escherichia coli</i>, <i>Pseudomonas aeruginosa</i>, <i>Bacillus subtilis</i>, and <i>Staphylococcus aureus</i> at various doses, as well as antifungal efficacy against <i>Aspergillus fumigates</i>. When compared to doxorubicin, the lung cancer cell lines (A549 cell line) demonstrated potential anticancer activity of silver nanoparticles.</p><h3>Conclusion</h3><p>We discovered that silver nanoparticles made from <i>Artocarpus altilis</i> fruit extract have a similar effect to ciprofloxacin. The cytotoxic activity anticipated against the lung cancer cell line (A549 cell line) shows that the percentage of cell viability is identical to that of doxorubicin which indicates the potential for the treatment of lung tumors.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"19 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140315201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Novel CFD Model of SMX Static Mixer Used in Advanced Continuous Manufacturing of Active Pharmaceutical Ingredients (API) 用于活性药物成分 (API) 先进连续生产的 SMX 静态混合器的新型 CFD 模型
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-23 DOI: 10.1007/s12247-024-09813-1
Athanasios Kritikos, Ravendra Singh, George Tsilomelekis, Fernando J. Muzzio

Purpose

The growing demand for effective pharmaceutical treatments, notably amidst health challenges like COVID, highlights the urgency for improved drug production techniques. This study examines the simulation of the Sulzer SMX static mixer in laminar conditions for the continuous pharmaceutical manufacturing of significant pharmaceuticals, notably imatinib.

Methods

Computational fluid dynamics (CFD) were employed to assess the SMX static mixer’s hydrodynamics and mixing performance. Emphasis was on mixing efficiency and residence time distributions (RTD) in a mixer with SMX elements. We refined the model’s reliability and explored the correlation between friction factor and Reynolds number. The Definitive Screening Design (DSD) was used to determine major factors impacting mixer dynamics.

Results

We established a novel correlation between friction factor and Reynolds number. The study reveal that lower flowrates significantly impact mixing efficiency, with different solvents inducing mixing delays. The RTD study identified the total inlet flowrate’s influence on distribution, with higher flowrates leading to more distinct RTD profiles and decreased axial mixing. The screening analysis highlighted flowrate’s dominance over other factors in determining mixing efficiency and residence time.

Conclusions

Through precise computational fluid dynamics (CFD) simulations, the study affirms the robustness of the developed model and underscores the novel correlation between the friction factor and Reynolds number. Insights into flow rate’s pivotal role in dictating mixer efficiency and residence time distribution are discerned, culminating in a comprehensive guide for refining static mixer operations for optimized drug manufacturing.

目的有效药物治疗的需求日益增长,特别是在 COVID 等健康挑战下,这凸显了改进药物生产技术的紧迫性。本研究对 Sulzer SMX 静态混合器在层流条件下连续生产重要药物(尤其是伊马替尼)的模拟情况进行了研究。方法采用计算流体动力学(CFD)评估 SMX 静态混合器的流体动力学和混合性能。重点是 SMX 混合器中的混合效率和停留时间分布 (RTD)。我们改进了模型的可靠性,并探索了摩擦因数和雷诺数之间的相关性。结果我们在摩擦因数和雷诺数之间建立了一种新的相关关系。研究表明,较低的流速会显著影响混合效率,不同的溶剂会导致混合延迟。热电阻研究确定了总入口流速对分布的影响,流速越高,热电阻曲线越明显,轴向混合越少。通过精确的计算流体动力学(CFD)模拟,研究证实了所开发模型的稳健性,并强调了摩擦因数与雷诺数之间的新型关联。研究深入揭示了流速在决定混合器效率和停留时间分布方面的关键作用,最终为改进静态混合器操作以优化药物生产提供了全面指导。
{"title":"A Novel CFD Model of SMX Static Mixer Used in Advanced Continuous Manufacturing of Active Pharmaceutical Ingredients (API)","authors":"Athanasios Kritikos,&nbsp;Ravendra Singh,&nbsp;George Tsilomelekis,&nbsp;Fernando J. Muzzio","doi":"10.1007/s12247-024-09813-1","DOIUrl":"10.1007/s12247-024-09813-1","url":null,"abstract":"<div><h3>Purpose</h3><p>The growing demand for effective pharmaceutical treatments, notably amidst health challenges like COVID, highlights the urgency for improved drug production techniques. This study examines the simulation of the Sulzer SMX static mixer in laminar conditions for the continuous pharmaceutical manufacturing of significant pharmaceuticals, notably imatinib.</p><h3>Methods</h3><p>Computational fluid dynamics (CFD) were employed to assess the SMX static mixer’s hydrodynamics and mixing performance. Emphasis was on mixing efficiency and residence time distributions (RTD) in a mixer with SMX elements. We refined the model’s reliability and explored the correlation between friction factor and Reynolds number. The Definitive Screening Design (DSD) was used to determine major factors impacting mixer dynamics.</p><h3>Results</h3><p>We established a novel correlation between friction factor and Reynolds number. The study reveal that lower flowrates significantly impact mixing efficiency, with different solvents inducing mixing delays. The RTD study identified the total inlet flowrate’s influence on distribution, with higher flowrates leading to more distinct RTD profiles and decreased axial mixing. The screening analysis highlighted flowrate’s dominance over other factors in determining mixing efficiency and residence time.</p><h3>Conclusions</h3><p>Through precise computational fluid dynamics (CFD) simulations, the study affirms the robustness of the developed model and underscores the novel correlation between the friction factor and Reynolds number. Insights into flow rate’s pivotal role in dictating mixer efficiency and residence time distribution are discerned, culminating in a comprehensive guide for refining static mixer operations for optimized drug manufacturing.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"19 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140200536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Pharmaceutical Innovation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1